Amgen's Q4 2024 earnings show a 19% revenue increase year-on-year, with non-GAAP EPS up 13% in Q4 and 6% for the full year.

Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...

In the first half of 2025, Ozempic developer Novo Nordisk in Bagsværd, Denmark, expects results from a second phase III trial ...

Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...

Q4 2024 Earnings Call Transcript February 4, 2025 Amgen Inc. beats earnings expectations. Reported EPS is $5.31, expectations ...

All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...

Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2024 versus comparable periods in 2023.

These launches are positioned for multi-blockbuster status, thanks to their promise of fulfilling unmet needs, impacting ...

Shares of Amgen (Nasdaq: AMGN) started crashing in early November and didn’t improve when the company released data from a phase 2 clinical trial for its weight-loss candidate MariTide.

Its pipeline progress, especially its obesity drug MariTide, positions Amgen, Inc. (NASDAQ:AMGN) for long-term growth. The company’s move towards rare diseases exhibited strong momentum in late ...

Shares of Amgen started crashing in early November and didn’t improve when the company released data from a Phase 2 clinical trial for its weight-loss candidate MariTide. That plunge has set the ...

Its pipeline progress, especially its obesity drug MariTide, positions Amgen Inc. (NASDAQ:AMGN) for long-term growth. The company’s move towards rare diseases exhibited strong momentum in late ...